Conference Coverage

First-line ramucirumab nets small PFS benefit in gastric cancer

Publish date: January 29, 2018

 

REPORTING FROM THE 2018 GI CANCERS SYMPOSIUM

SOURCE: Fuchs CS et al. GI CANCERS SYMPOSIUM Abstract 5

Pages

Recommended Reading

Pembrolizumab for dMMR/MSI-H tumors marks first tumor agnostic FDA approval
MDedge Hematology and Oncology
Expanding treatment options for diverse neuroendocrine tumors
MDedge Hematology and Oncology
Study: Test carcinoembryonic antigen in colon cancer after surgery
MDedge Hematology and Oncology
S-1 regimen noninferior to other frontline mCRC options
MDedge Hematology and Oncology
New multi-analyte blood test shows promise in screening for several common solid tumors
MDedge Hematology and Oncology
Circulating tumor cell assay shows promise for colorectal cancer screening
MDedge Hematology and Oncology
FDA approves lutetium Lu 177 dotatate for GEP-NETs
MDedge Hematology and Oncology
Combination immunotherapy is active in dMMR/MSI-H metastatic colorectal cancer
MDedge Hematology and Oncology
Pembrolizumab plus SBRT shows promise for advanced solid tumors
MDedge Hematology and Oncology
Right-sided CRC has poorer disease-free survival after adjuvant chemo
MDedge Hematology and Oncology